News | Prostate Cancer | December 18, 2015

Cancer Targeted Technology Receives $2.3 Million Small Business Fast-Track Contract to Develop an Innovative PSMA-Targeted Radionuclide Therapy for Prostate Cancer

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute awarded a 27-month, $2.3M contract to CTT to develop a new agent that will help treat metastatic prostate cancer. Prostate cancer is the most commonly diagnosed cancer and second leading cause of cancer death in men. The cancer is radiosensitive but no radiotherapy to date specifically targets this cancer. CTT is developing molecules that bind Prostate-Specific Membrane Antigen (PSMA) for the specific delivery of diagnostic and therapeutic agents. PSMA is an excellent biomarker as its expression is minimal to negative on normal tissues, but is over-expressed on prostate cancer and expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s unique phosphoramidate-based agents, discovered by Cliff Berkman, M.d., professor of chemistry, Washington State University, bind irreversibly to PSMA. Unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells, leading to increased accumulation of the therapeutic payload within the tumor and improved efficacy, with minimal side effects to healthy tissues.

CTT is excited to work with Carolyn Anderson, M.D., professor of radiology and head of the Molecular Imaging Laboratory at the University of Pittsburgh, on this contract. Anderson’s group, working in state-of-the-art facilities, will radiolabel and evaluate CTT’s agents in preclinical prostate tumor models and will monitor the efficacy in conjunction with CTT’s diagnostic imaging agent.

This contract optimizes the lead agent, CTT1401, to specifically deliver a therapeutic dose of the radionuclide, 177Lu, to prostate tumors and will advance this compound to an Investigational New Drug application that would support a clinical trial in metastatic prostate cancer. The radiotherapeutic agent will be used in conjunction with CTT’s companion diagnostic Positron Emission Tomography imaging agent, CTT1057 (set to commence clinical trials in prostate cancer patients in early 2016).

“Although new treatments have emerged for metastatic prostate cancer, overall survival rates remain poor. A specific means of treating this disease that minimizes side effects and results in a meaningful increase in quality of life and life expectancy is needed, and we believe CTT’s new radiotherapy agent will accomplish this goal,” stated Beatrice Langton-Webster, M.d., CTT’s chief executive officer and principal investigator on the contract.

For more information: www.cancertargetedtechnology.com

Related Content

RayStation Selected for New Tennessee Proton Therapy Center
News | Treatment Planning | November 20, 2017
November 20, 2017 — Provision Healthcare has selected RayStation for external beam planning at the new Provision Care
Sponsored Content | Videos | Radiation Therapy | November 15, 2017
Chris Toth, president, global commercial and field operations for Varian, takes a tour of Varian’s new product introd
Synthetic CT Images Suitable for Prostate Cancer Radiotherapy Planning
News | Treatment Planning | November 14, 2017
Spectronic Medical announced that new data for their MRIPlanner software, generating synthetic computed tomography (sCT...
ASTRO: CMS Report on Radiation Therapy Payment Model Charts Path to Value-Based Cancer Care
News | Radiation Therapy | November 08, 2017
The American Society for Radiation Oncology (ASTRO) called on the Centers for Medicare and Medicaid Services (CMS) to...
U.S. Recognizes Radiologic Technologists Nov. 5-11
News | Imaging | November 06, 2017
November 6, 2017 — During National Radiologic Technology Week (NRTW) every November, hospitals, healthcare centers an
Study Suggests Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust
News | Radiation Therapy | November 06, 2017
November 6, 2017 — Nearly one-third of women with...
PTCOG-NA Studies Address Cost and Coverage Issues With Proton Therapy
News | Proton Therapy | November 01, 2017
Physicians from across the country gathered in Chicago last week to discuss the most recent advances in proton therapy...
Proton Therapy Lowers Treatment Side Effects in Pediatric Head and Neck Cancer Patients
News | Proton Therapy | November 01, 2017
Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional...
Cleveland Clinic Leads Development of New Guidelines for Radiation in Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 31, 2017
October 31, 2017 — Cleveland Clinic researcher Chirag Shah, M.D., recently led the development of updated guidelines
Proton Therapy Shows Promising Clinical Benefits for Esophageal, Prostate and Breast Cancer
News | Proton Therapy | October 30, 2017
The National Association for Proton Therapy (NAPT) announced a number of clinical papers showing promising results were...
Overlay Init